.Merck defeats revenues desires, rears purchases expectation on solid need for leading drugs like Keytruda CNBCMerck & Co. (MRK US) Defeats Profit Forecasts as Keytruda Purchases Rise BloombergMerck Sell: Pharma Giant Posts Sturdy Outcomes, However Outlook Drops Short Client's Business DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck trumps revenue and purchases requirements surrounded by Keytruda asset, but provides blended full-year overview MarketWatch.